The earnings call reflected a positive outlook with significant achievements, particularly the successful Phase III trial for Tebipenem HBr and the improved financial metrics. However, challenges remain in the SPR720 program. Overall, the positive developments notably outweigh the negative aspects.

Company Guidance

During Spero Therapeutics' second quarter 2025 earnings call, significant progress was highlighted, particularly in their lead clinical program for Tebipenem HBr targeting complicated urinary tract infections (cUTIs). The Phase III PIVOT-PO trial was stopped early for efficacy, demonstrating Tebipenem HBr's non-inferiority to intravenous imipenem-cilastatin, with primary endpoint achievement noted in a test of cure visit. The trial's early conclusion resulted in cost savings, extending the company's cash runway into 2028. Financially, Spero reported a second-quarter revenue of $14.2 million, up from $10.2 million in the prior year, mainly due to collaboration revenue from GSK. R&D expenses decreased from $23.7 million to $10.7 million year-over-year, while G&A expenses slightly increased to $5.9 million. The net loss narrowed significantly to $1.7 million from $17.9 million in the previous year, with a diluted net loss per share of $0.03 compared to $0.33. Looking ahead, Spero focuses on regulatory approval of Tebipenem HBr, with FDA action anticipated in the second half of 2026, supported by contingent milestone opportunities with GSK, potentially totaling $351 million.

Successful Phase III PIVOT-PO Trial for Tebipenem HBr

The Phase III PIVOT-PO trial evaluating Tebipenem HBr for complicated urinary tract infections met its primary endpoint and was stopped early for efficacy, demonstrating non-inferiority to intravenous imipenem-cilastatin.

Extended Cash Runway

With the trial stopping early for efficacy, Spero achieved meaningful cost savings, extending the cash runway into 2028 based on their current operating plan.

Increased Revenue

Total revenue for the second quarter of 2025 was $14.2 million compared to $10.2 million for the second quarter of 2024, primarily due to collaboration revenue from GSK.

Reduction in Net Loss

Spero reported a net loss of $1.7 million for the second quarter of 2025 compared to a net loss of $17.9 million for the second quarter of 2024.

Significant R&D Expense Reduction

R&D expenses for the second quarter of 2025 were $10.7 million compared to $23.7 million for the same period in 2024, primarily due to reduced clinical expense related to the PIVOT-PO study.

Spero Therapeutics (SPRO) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

SPRO Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 17, 2025	2025 (Q3)	-0.25 / -	-0.32	―	―	―
Aug 12, 2025	2025 (Q2)	-0.38 / -0.03	-0.33	90.91% (+0.30)	―
May 13, 2025	2025 (Q1)	-0.55 / -0.25	-0.24	-4.17% (-0.01)	―	―
Mar 27, 2025	2024 (Q4)	-0.31 / -0.38	0.96	-139.58% (-1.34)	―
Nov 14, 2024	2024 (Q3)	-0.27 / -0.32	-0.06	-433.33% (-0.26)	―	―
Aug 05, 2024	2024 (Q2)	-0.38 / -0.33	-0.23	-43.48% (-0.10)	―
May 15, 2024	2024 (Q1)	-0.04 / -0.24	-0.25	4.00% (+0.01)	―	―
Mar 13, 2024	2023 (Q4)	-0.10 / 0.96	0.55	74.55% (+0.41)	―
Nov 13, 2023	2023 (Q3)	-0.03 / -0.06	-0.33	81.82% (+0.27)	―
Aug 10, 2023	2023 (Q2)	-0.34 / -0.23	-0.87	73.56% (+0.64)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

SPRO Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 12, 2025	$2.36	$1.94	-17.80%
May 13, 2025	$0.69	$0.65	-5.80%
Mar 27, 2025	$0.86	$0.77	-10.47%
Nov 14, 2024	$1.25	$1.18	-5.60%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Spero Therapeutics (SPRO) report earnings?

Spero Therapeutics (SPRO) is schdueled to report earning on Nov 17, 2025, TBA (Confirmed).

What is Spero Therapeutics (SPRO) earnings time?

Spero Therapeutics (SPRO) earnings time is at Nov 17, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is SPRO EPS forecast?

SPRO EPS forecast for the fiscal quarter 2025 (Q3) is -0.25.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing